Core Viewpoint - Nova Star Cloud (301589) is actively managing its supply chain by collaborating with multiple strategic suppliers for key raw materials to ensure supply stability and is closely monitoring price fluctuations of these materials [1] Group 1: Supply Chain Management - The company has established partnerships with several strategic suppliers to secure the stability of its supply chain [1] - Nova Star Cloud is implementing proactive strategies in response to changes in the prices of key raw materials [1] Group 2: Product Development - The company is exploring high-value-added areas in downstream scenarios to develop high-margin products [1] - Specific details regarding the company's product gross margin will be available in future periodic reports [1]

在截至2025年12月27日的这个季度（2026财年第一季度），苹果总营收1437.56亿美元，较上年同期的 1243亿美元同比增长16%，超过市场预期的1384亿美元，创下苹果公司历史最高季度营收；净利润为 420.97亿美元，较上年同期的363.30亿美元同比增长15.9%，相当于平均每天净赚4.63亿美元（约合人民 币32亿元）。 "大大超越了我们的期待。"对于这份出的的季度业绩，苹果CEO蒂姆·库克表示："受前所未有的市场需 求推动，iPhone迎来史上最佳季度表现，各地区营收均刷新历史纪录；服务业务营收同样创下历史新 高，同比增长14%。" 另外，在这一季度，苹果的活跃设备现有使用量已超过25亿台。 创纪录的业绩表现和强劲的利润率推动苹果美股收益2.84美元，同比增长19%，亦创下新高，同时给苹 果带来了近540亿美元的经营现金流，并向股东回报近320亿美元。 iPhone 17系列热销 时值美股Q4财报季，多份超预期业绩先后出炉。继微软、Meta、特斯拉之后，当地时间1月29日，全球 科技和消费电子巨头苹果交出了一份创纪录的最新成绩单。 从各个区域市场来看，这一季度，大中华区的表现尤为亮眼——营收 ...

证券日报网讯1月30日，阳光电源（300274）在互动平台回答投资者提问时表示，公司跟合作伙伴有长 期协议和年度框架协议保障供应，未来如果原材料涨价，公司依托规模优势和优秀的供应链管理能力能 保持供应链竞争优势。当原材料成本发生显著变动时，公司会积极与客户沟通，相较于同行，公司在品 牌、产品及供应链层面均具备优势，有信心做好适度传导。 ...

九彩果鲜在市场中的竞争优势是什么？ 九彩果鲜通过优质产品、稳定供应链和多渠道销售策略，在市场中获得了较强的竞争优势，确保了其生 存能力。 九彩果鲜采用了独特的经营模式，结合线上线下渠道，打造了全方位的销售体系。公司通过建立强大的 供应链管理，实现了从产地到消费者手中的高效流转。与此同时，九彩果鲜具有严格的产品质量监控体 系，确保每一批水果都符合标准，提高了消费者的信任度。此外，该品牌在市场上展现出强大的竞争 力，提供差异化的产品和服务，比如长期稳定的合作关系及良好的售后服务，从而进一步增强用户黏 性。这种灵活多变的经营策略，使九彩果鲜在竞争激烈的市场环境中始终保持领先地位。 九彩果鲜凭借其优质的产品和稳定的供应链，展现了强劲的生存能力。通过采用现代冷链物流和区块链 技术，九彩果鲜确保了产品的新鲜度和品质，使得客户的损耗风险大幅降低。此外，九彩果鲜与多个优 秀的农批市场保持紧密合作，这为其在竞争激烈的市场中立足提供了保障。展望未来，九彩果鲜计划进 一步拓展销售网络，深入开发华南及西南地区，从而增强品牌影响力和市场份额。结合以上策略，可以 看出九彩果鲜具备良好的发展潜力，有望在生鲜水果市场上继续保持领先地位。 九 ...

Core Viewpoint - Wanchen Group expects a net profit attributable to shareholders of 1.23 billion to 1.4 billion yuan for the fiscal year 2025, indicating strong growth prospects in its retail snack business and improvements in its mushroom business [1] Group 1: Retail Snack Business - In 2025, the company anticipates significant sales growth in its retail snack business, with expected revenue between 50 billion to 52 billion yuan, representing a year-on-year increase of 57.28% to 63.57% [1] - The company is focusing on enhancing its core competencies, including supply chain management, logistics, digitalization, and brand empowerment, which are expected to drive sales and profit margins [1] - The net profit for the retail snack business is projected to be between 2.2 billion to 2.6 billion yuan, with a net profit margin of 4.40% to 5.10% after accounting for stock payment expenses [1] Group 2: Mushroom Business - The mushroom industry is expected to stabilize and recover in the second half of 2025 after a prolonged market adjustment [1] - As market conditions improve, the company anticipates an increase in sales prices and gross profit margins for its main mushroom products, leading to better operational performance [1]

Core Insights - Boeing reported a surprising profit of $9.92 per share for Q4, significantly exceeding analysts' expectations of a $0.39 per share loss, primarily due to a one-time business gain of $9.6 billion [1][5] Financial Performance - Boeing's total revenue for 2025 reached $89.5 billion, marking a 34% increase from 2024, with net earnings of $2.2 billion compared to a loss of $11.8 billion in 2024 [3] - The company achieved a Q4 revenue of $23.9 billion, contributing to a record-high backlog of $682 billion, indicating strong demand for its aircraft [7] Production and Deliveries - The production rate of the 737 MAX is set to increase from 42 to 47 aircraft per month, while the total commercial deliveries rose by 72%, totaling 600 planes for the year [2][4] - The 787 program maintained a production rate of 8 planes per month, with the 777X program expected to commence in 2027 [4] Segment Performance - Boeing's Commercial Airplanes (BCA) segment reported a loss of $632 million in Q4, while the Defense, Space & Security (BDS) segment incurred a loss of $507 million, largely due to costs associated with the KC-46A Tanker program [5][6] - The Global Services (BGS) segment generated $5.2 billion in revenue, serving as a key profit driver for the company [6] Supply Chain and Strategic Moves - The U.S. government's $1.6 billion investment in USA Rare Earth is expected to help Boeing mitigate supply chain risks related to rare-earth magnets, which are critical for various aircraft systems [2][8] - Boeing's reliance on rare-earth materials exposes it to price volatility and supply risks, particularly due to export controls from China [8]

Core Insights - Coosea Intelligent positions itself as an "enabler behind local brands" amidst the transition from "Made in China" to "Intelligent Manufacturing in China" [1] - The company leverages China's supply chain advantages and has established a stable and efficient supply chain system through long-term partnerships with key component suppliers [1] - Coosea Intelligent has a strong focus on technology research and product innovation, holding over 100 patents and increasing R&D investment to 225.9 million yuan from 2022 to 2024 [2] Supply Chain Management - The foundation of Coosea's international expansion is its deep reliance on China's supply chain, which has been developed over nearly two decades [1] - The company utilizes digital tools such as ERP systems and SRM digital procurement platforms to achieve visual management of the entire material process and online supply-demand collaboration, significantly enhancing procurement and delivery efficiency [1] - This supply chain model combines stability and flexibility, serving as a core support for navigating complex global trade environments [1] Research and Development - Coosea Intelligent is recognized as a national-level specialized and innovative "little giant" enterprise, possessing full-stack R&D design capabilities [2] - The company has a unique product definition ability, tailoring products to meet local demands based on an understanding of different countries' consumption levels and cultural characteristics [2] - Coosea can efficiently respond to customization needs, completing modifications to existing models within three months and developing new models within six months [2]

Financial Data and Key Metrics Changes - Total sales for Q4 2025 were $373.2 million, a year-over-year increase of 7.9% as reported and 7.1% in constant currency [6] - For the full year, sales reached $1.375 billion, representing a year-over-year growth of 5.2% as reported and 5.1% in constant currency [6] - Adjusted earnings per share (EPS) for Q4 were $1.43, growing 6.7%, while full-year adjusted EPS was $4.59, an increase of 10.1% [6][23] Business Line Data and Key Metrics Changes - Orthopedic sales increased by 12.1% in Q4 and 5.5% for the full year on a constant currency basis [6] - General surgery sales grew by 3.8% in Q4 and 4.7% for the full year in constant currency [6] - U.S. orthopedic sales grew 6.6%, while international orthopedic sales increased 15.7% in Q4 [17] - U.S. general surgery sales declined by 0.4%, while international sales increased by 14.8% in Q4 [18] Market Data and Key Metrics Changes - International sales grew 15.4% in Q4, while U.S. sales increased by 1.4% [17] - The decline in U.S. general surgery was attributed to a focus on exiting non-core product lines [18] Company Strategy and Development Direction - The company plans to focus on high-growth, high-margin markets such as robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair [7] - A strategic decision was made to exit the gastroenterology product lines to concentrate resources on stronger growth drivers, expected to improve long-term growth margins by approximately 80 basis points [7][8] - The company aims to stabilize and scale its supply chain while building a high-performance, agile supply chain to support sustained innovation [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving above-market growth by focusing on core strengths and normalizing supply in sports medicine [15] - The company anticipates continued growth in its AirSeal and BioBrace platforms, with AirSeal expected to deliver high single-digit to low double-digit growth rates [10][13] - The CFO transition is underway, with a focus on maintaining continuity and shareholder value [16] Other Important Information - The company suspended its dividend and approved a $150 million share repurchase authorization, equating to approximately $0.07 EPS in 2026 [15] - Adjusted gross margin for Q4 was 56.6%, down 100 basis points from the prior year, while full-year adjusted gross margin was 56.4%, an increase of 10 basis points [21] Q&A Session Summary Question: Can you discuss the cadence for the rest of the year and any selling day differences? - Management confirmed no selling day differences and indicated that the rest of the year should follow the typical med tech calendar [32] Question: What is the status of the CFO search? - The company is actively searching for a new CFO who will focus on shareholder value and be a strong team player [34] Question: Can you clarify the organic revenue numbers presented at the healthcare conference versus today? - The difference is due to final numbers rolling out, with the current guidance being more precise [37] Question: What drove the upside in orthopedic sales and the downside in general surgery? - The orthopedic sales beat was attributed to committed sales professionals, improving supply chain, and new product approvals, while general surgery faced challenges due to portfolio management [40][42] Question: How will the GI business be reported going forward? - The GI business will be reported separately, reflecting its exit from the main revenue figures [54] Question: What are the growth trends for AirSeal internationally? - AirSeal continues to perform within the expected growth range, with opportunities in both robotic and laparoscopic procedures [68]

Financial Data and Key Metrics Changes - Total sales for Q4 2025 were $373.2 million, a year-over-year increase of 7.9% as reported and 7.1% in constant currency [5] - For the full year, sales were $1.375 billion, representing year-over-year growth of 5.2% as reported and 5.1% in constant currency [5] - Adjusted earnings per share for Q4 were $1.43, growing 6.7%, while full-year adjusted EPS was $4.59, growing 10.1% [5][21] - GAAP net income for Q4 was $16.7 million, down from $33.8 million in Q4 2024, with GAAP earnings per diluted share at $0.54 compared to $1.08 a year ago [19] Business Line Data and Key Metrics Changes - Orthopedic sales increased 12.1% in Q4 and 5.5% for the full year on a constant currency basis [5] - General surgery sales increased 3.8% in Q4 and 4.7% for the full year in constant currency [5] - U.S. orthopedic sales grew 6.6% in Q4, while international orthopedic sales increased 15.7% [16] - U.S. general surgery sales declined 0.4%, while international general surgery sales increased 14.8% [16] Market Data and Key Metrics Changes - International sales grew 15.4% in Q4, while U.S. sales increased 1.4% [15] - The decline in U.S. general surgery was attributed to a focus on non-core areas and strategic portfolio management [16] Company Strategy and Development Direction - The company plans to exit its gastroenterology product lines to focus on high-growth, high-margin markets such as robotic and laparoscopic surgery [6][7] - The strategy includes stabilizing and scaling operations to build a high-performance supply chain [8] - The company aims to deliver sustained above-market growth in its orthopedic portfolio over time [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to return to above-market growth by focusing on core strengths and investing in high-growth platforms [13] - The company is optimistic about the long-term growth potential of its AirSeal and BioBrace products, with expectations of high single-digit to low double-digit growth rates [10][12] Other Important Information - The company suspended its dividend and approved a $150 million share repurchase authorization [12] - The leverage ratio at the end of the year was 2.9 times, providing flexibility for innovation and growth [12] Q&A Session Summary Question: Can you talk about the cadence for the rest of the year and any selling day differences? - Management indicated no selling day differences and expected normal seasonality for the med tech calendar [30] Question: What is the status of the CFO search? - The company is actively searching for a new CFO who will focus on shareholder value and be a strong teammate to the leadership team [32] Question: Can you clarify the organic revenue numbers presented at the healthcare conference versus today? - The difference was due to final numbers rolling out, with the current guidance being more precise [35] Question: What drove the upside in orthopedic sales and the downside in general surgery? - The orthopedic sales beat was attributed to committed sales professionals, improving supply chain, and new product approvals, while general surgery faced challenges due to portfolio management [37][40] Question: How will the GI business be reported going forward? - The GI business will be reported separately as the company moves forward [54]

证券日报网讯 1月28日，商络电子在互动平台回答投资者提问时表示，公司核心优势体现在以下几个方 面。客户资源：为超5000家客户提供分销服务，覆盖汽车电子、工业控制、消费电子、移动通讯等众多 领域，服务于各行业龙头客户；品牌授权优势：积累国内外优质原厂授权资质，代理产品线超110条； 供应链管理能力：数字化团队通过部署先进供应链管理系统、开发定制化平台，持续提升运营效率；风 险控制：建立全流程风险管控措施，从原厂品质、物料管理、客户信用等环节全面防控风险。未来，公 司将深耕高附加值赛道，强化供应链壁垒与技术增值服务，以可持续业绩夯实市值基础，提升股东回 报。 （编辑 姚尧） ...